Stockreport

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic [Read more]